Title: Clevidipine
CAS Registry Number: 167221-71-8
CAS Name: 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl (1-oxybutoxy)methyl ester
Additional Names: butyroxymethyl methyl 4-(2¢,3¢-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
Trademarks: Clevelox (AstraZeneca)
Molecular Formula: C21H23Cl2NO6
Molecular Weight: 456.32
Percent Composition: C 55.27%, H 5.08%, Cl 15.54%, N 3.07%, O 21.04%
Literature References: Ultrashort-acting dihydropyridine calcium channel antagonist. Prepn: K. H. Andersson et al., WO 9512578; eidem, US 5856346 (1995, 1999 both to Astra). Improved prepn: A. Mattson et al., WO 0031035 (2000 to AstraZeneca). Capillary GC/MS determn in whole blood: C. Fakt, H. Stenhoff, J. Chromatogr. B 723, 211 (1999). Clinical pharmacokinetics: H. Ericsson et al., Br. J. Clin. Pharmacol. 47, 531 (1999); and pulmonary extraction during cardiopulmonary bypass: A. Vuylsteke et al., Br. J. Anaesth. 85, 683 (2000). Clinical evaluation in hypertension in postoperative cardiac surgical patients: N. Kieler-Jensen et al., Acta Anaesthesiol. Scand. 44, 186 (2000); J. M. Bailey et al., Anesthesiology 96, 1086 (2002). Review of pharmacology and clinical development: M. Nordlander et al., Cardiovasc. Drug Rev. 22, 227-250 (2004).
Properties: Crystals from diisopropylether, mp 136.2-138.5°. Soly in water: 0.1 mg/ml.
Melting point: mp 136.2-138.5°
Therap-Cat: Antihypertensive.
Keywords: Antihypertensive; Dihydropyridine Derivatives; Calcium Channel Blocker; Dihydropyridine Derivatives. |